Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Phoenixus","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Vyera Pharmaceuticals, LLC and Phoenixus AG Sign Asset Purchase Agreement to Sell Rights to Daraprim and Vecamyl","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Tilde Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tilde Sciences Acquires Daraprim\u00ae and Vecamyl\u00ae from Vyera Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim\u00ae in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Tox21_300129

    Menu

    Tox21_300129

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dr. Reddy's Laboratories

              Contact Supplier
              • Development Update
              Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim® in the U.S. Market

              Details:

              Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. This product is the only ABrated generic version Daraprim® (pyrimethamine) Tablets approved by the USFDA.

              Lead Product(s): Pyrimethamine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Pyrimethamine-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 20, 2020

              Dr Reddy Company Banner

              CPhI North America

              Attending

              envelop Contact Supplier

              Vyera Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tilde Sciences Acquires Daraprim® and Vecamyl® from Vyera Pharmaceuticals

              Details:

              Through the acquisition, Tilda Sciences gain two medicines, Daraprim (pyrimethamine), approved for treatment of toxoplasmosis and Vecamyl (mecamylamine HCI), approved for management of hypertension, from Vyera Pharmaceuticals.

              Lead Product(s): Pyrimethamine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Daraprim

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Tilde Sciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vyera Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vyera Pharmaceuticals, LLC and Phoenixus AG Sign Asset Purchase Agreement to Sell Rights to Daraprim and Vecamyl

              Details:

              Through the agreement, Phoenixus gains access to Daraprim, a prescription medication that contains pyrimethamine for the treatment of toxoplasmosis and Vecamyl (mecamylamine HCI), indicated for the management of moderately severe to severe essential hypertension.

              Lead Product(s): Pyrimethamine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Daraprim

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Phoenixus

              Deal Size: $0.6 million Upfront Cash: Undisclosed

              Deal Type: Agreement August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY